Home » Stocks » VXRT

Vaxart, Inc. (VXRT)

Stock Price: $7.55 USD 0.40 (5.59%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
Pre-market: $7.56 +0.01 (0.13%) Mar 2, 5:22 AM
Market Cap 771.63M
Revenue (ttm) 4.05M
Net Income (ttm) -32.22M
Shares Out 88.30M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE 44.64
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $7.55
Previous Close $7.15
Change ($) 0.40
Change (%) 5.59%
Day's Open 7.41
Day's Range 7.08 - 7.64
Day's Volume 5,783,321
52-Week Range 1.08 - 24.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 23 minutes ago

VAXART, INC. (VXRT) witnessed a jump in share price last session on above-average trading volume.

Forbes - 19 hours ago

Vaxart stock (NASDAQ: VXRT) dropped -8% over the last five trading days and has underperformed the S&P 500 which remained roughly flat over the same period. The stock is also down by about -27...

The Motley Fool - 23 hours ago

The short answer: maybe.

GlobeNewsWire - 5 days ago

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather ...

The Motley Fool - 5 days ago

Let's look at what short-sellers are saying and what science is saying.

Zacks Investment Research - 6 days ago

In the latest trading session, VAXART, INC. (VXRT) closed at $6.79, marking a -0.73% move from the previous day.

Zacks Investment Research - 1 week ago

VAXART, INC. (VXRT) closed the most recent trading day at $7.94, moving -1.85% from the previous trading session.

Zacks Investment Research - 1 week ago

SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.

Other stocks mentioned: BIGC, GME, MRNA, NVAX, SHOP
Zacks Investment Research - 1 week ago

On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.

The Motley Fool - 2 weeks ago

The choice isn't easy, but simplicity may be the answer.

Other stocks mentioned: INO
The Motley Fool - 2 weeks ago

The company can still produce returns without a COVID vaccine.

The Motley Fool - 2 weeks ago

The short answer: Yes.

Forbes - 2 weeks ago

Biotech company Vaxart posted mixed phase 1 results for its tablet-based Covid-19 vaccine, causing its stock to decline by over 60% from last week's high. Although the vaccine was well tolerat...

The Motley Fool - 2 weeks ago

The once high-flying biotech stock has crashed.

The Motley Fool - 3 weeks ago

The stock lost more than half its value in one trading session.

Other stocks mentioned: GME, MRNA, NVAX, PFE
The Motley Fool - 3 weeks ago

Hope for an oral COVID-19 vaccine remains alive.

The Motley Fool - 3 weeks ago

This small-cap biotech just published clinical data for its experimental coronavirus vaccine, and investors are not happy.

The Motley Fool - 3 weeks ago

Results from a phase 1 study show that the biotech's vaccine candidate, VXA-CoV2-1, falls short in one crucial area.

The Motley Fool - 3 weeks ago

The biotech really needs some good news.

The Motley Fool - 3 weeks ago

The coronavirus vaccine maker reported disappointing clinical trial results.

Zacks Investment Research - 3 weeks ago

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Other stocks mentioned: AVXL, AXSM, HOLX, MRNA, NVAX, SAVA, VIVO
InvestorPlace - 3 weeks ago

Following short-squeeze hopes on Tuesday, Vaxart stock was down Wednesday on news of preliminary Phase I vaccine trial results. The post VXRT Stock: What To Know As Covid-19 Play Vaxart Plumme...

Investors Business Daily - 3 weeks ago

Vaxart stock crumbled Wednesday after the company said its coronavirus vaccine didn't generate detectable neutralizing antibodies in "most subjects." The post Vaxart Stock Crashes After Oral C...

CNBC - 3 weeks ago

The vaccine, which comes in the form of a small tablet, generated a type of T-cell responsible for destroying virus-infected cells in about 75% of volunteers.

GlobeNewsWire - 3 weeks ago

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today annou...

InvestorPlace - 3 weeks ago

Vaxart (VXRT) stock is heading higher Tuesday and there are a couple of things investors will want to keep in mind about the biotech company. The post VXRT Stock Alert: 2 Things for Vaxart Inv...

Forbes - 3 weeks ago

The GameStop short-squeeze saga has turned the spotlight on small and mid-cap stocks with a high level of short interest. Heavily shorted stocks could be targeted for so-called social trades b...

Other stocks mentioned: GOGO, M
The Motley Fool - 3 weeks ago

Probably not, if you're investing for the long term.

Other stocks mentioned: ARCT, INO
Seeking Alpha - 1 month ago

Two new breakout stocks for Week 5 of 2021 with better than 10% short-term upside potential. This past week all 4 stocks gained over 10% with NBSE and QDEL gaining over 20% before pulling back...

Other stocks mentioned: AAPL, AMGN, CAT, DOW, HD, HMY, JNJ, MRK, NVR, TRV, WMT
The Motley Fool - 1 month ago

They can't vaccinate the whole world against COVID-19 -- but they may vaccinate all of the U.S.

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, NVAX, PFE
The Motley Fool - 1 month ago

A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed?

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)-- #Investigation--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Vaxart, Inc. (NASDAQ: VX...

The Motley Fool - 1 month ago

After the stock's magnificent run in 2020, it might be time to take profits.

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vaxart, Inc. (NASDAQ: VXRT) concerning the Company and its directors' and officers' possible viola...

Forbes - 1 month ago

Biotech company Vaxart's stock has rallied by about 40% over the last 5 trading days, with a bulk of the gains coming on Monday. The stock is also up by about 76% since the beginning of 2021, ...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rat...

GlobeNewsWire - 1 month ago

New pre-clinical histology data show that Vaxart's oral vaccine protected against lung inflammation in hamster models

Forbes - 1 month ago

Biotech company Vaxart stock is up by over 11x through the last 12 months rising to levels of around $7 per share, driven by the company's efforts to develop a Covid-19 vaccine. Vaxart, which ...

The Motley Fool - 1 month ago

No kidding around ... here's how they truly can.

Other stocks mentioned: ALT, JUSHF
Seeking Alpha - 1 month ago

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors t...

Other stocks mentioned: BEEM, BLNK, CELH, CODX, CRDF, GNPX, GRWG, KIRK, MARA, NLS, NVAX, PLUG, RIOT, UAVS, VERI, WTRH
The Motley Fool - 1 month ago

These companies' vaccines could bring in billions of dollars in revenue.

Other stocks mentioned: NVAX
Investopedia - 1 month ago

These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.

Other stocks mentioned: ATEN, EYE, NVAX, SWBI, TROX, UIS, VERI, VHC
Zacks Investment Research - 1 month ago

Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.

The Motley Fool - 1 month ago

There are some warning signs around this vaccine-maker that investors should take seriously.

The Motley Fool - 1 month ago

Both of them already did it in 2020.

Other stocks mentioned: NVAX
The Motley Fool - 1 month ago

Can this small-cap biotech be part of the solution in the ongoing fight against COVID-19?

The Motley Fool - 1 month ago

This high-flying biotech stock just might have more room to run. But it's risky.

The Motley Fool - 1 month ago

Investors can start the new year off right by digging into these three small but fiery stocks.

Other stocks mentioned: CPRX, OGI
The Motley Fool - 1 month ago

The biotech stock could still have big gains ahead, and not just because of its COVID-19 vaccine candidate.

PRNewsWire - 1 month ago

SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, investigates potential claims against Vaxart, Inc. (NASDAQ: VXRT) for violations of federal securities ...

About VXRT

Vaxart, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
VXRT
Full Company Profile

Financial Performance

In 2020, Vaxart's revenue was $4.05 million, a decrease of -58.97% compared to the previous year's $9.86 million. Losses were -$32.22 million, 72.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Vaxart stock is "Strong Buy." The 12-month stock price forecast is 17.67, which is an increase of 134.04% from the latest price.

Price Target
$17.67
(134.04% upside)
Analyst Consensus: Strong Buy